Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients.

Abstract

AIM:

Although statins increase the plasma concentration of high-density lipoprotein cholesterol (HDL-C), it has not been elucidated whether the increased HDL particles possess normal antiatherosclerotic properties. Pitavastatin functions to increase the plasma HDL-C level and decrease the lowdensity lipoprotein cholesterol (LDL-C) level. In the present study, we sought to examine the qualitative changes in HDL during pitavastatin treatment.

METHODS:

A total of 30 patients with dyslipidemia were treated with 2 mg of pitavastatin for four weeks. The cholesterol efflux capacity and activities of the antioxidative enzymes paraoxonase-1 (PON-1) and platelet-activating factor acetylhydrolase (PAF-AH) were evaluated using polyethethylene glycol-treated HDL fractions before and after pitavastatin treatment.

RESULTS:

Pitavastatin treatment decreased the serum LDL-C level by 39% and increased the serum HDL-C level by 9% (p＜0.05). In addition, pitavastatin increased the phospholipid content of HDL by 7.8% (p＜0.05). The pitavastatin-induced increase in the HDL-C level coincided with an increase in the cholesterol efflux capacity of the isolated HDL fraction of 8.6% (p＜0.05). The post-pitavastatin treatment activity of HDL-associated PON-1 (paraoxonase and arylesterase) was increased by 9% (p＜0.05) and 11% (p＜0.05), respectively, while the HDL-associated PAF-AH activity was not affected by pitavastatin.

CONCLUSIONS:

In addition to its LDL-C-lowering effects, pitavastatin elevates the HDL-C level and enhances the cholesterol efflux capacity and antioxidative properties of HDL. Pitavastatin therefore increases the amount of functional HDL without attenuating HDL quality.

• Authors: Maki Miyamoto-Sasaki, Tomoyuki Yasuda, Tomoko Monguchi, Hideto Nakajima, Kenta Mori, Ryuji Toh, Tatsuro Ishida, Ken-ichi Hirata
• Journal: Journal of atherosclerosis and thrombosis (J Atheroscler Thromb) Vol. 20 Issue 9 Pg. 708-16 ( 2013) ISSN: 1880-3873 [Electronic] Japan
• PMID: 23739642 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antioxidants
• Cholesterol, HDL
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Platelet Activating Factor
• Quinolines
• Polyethylene Glycols
• Cholesterol
• 1-Alkyl-2-acetylglycerophosphocholine Esterase
• Aryldialkylphosphatase
• PON1 protein, human
• pitavastatin

Topics

• 1-Alkyl-2-acetylglycerophosphocholine Esterase (metabolism)
• Adult
• Aged
• Antioxidants (metabolism)
• Aryldialkylphosphatase (metabolism)
• Atherosclerosis (prevention & control)
• Cholesterol (metabolism)
• Cholesterol, HDL (drug effects)
• Dyslipidemias (drug therapy, metabolism)
• Female
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (pharmacology)
• Male
• Middle Aged
• Platelet Activating Factor (metabolism)
• Polyethylene Glycols (metabolism)
• Quinolines (pharmacology)